Skip to main content
. 2012 Mar 5;12(1):49–65. doi: 10.1102/1470-7330.2012.0007

Figure 4.

Figure 4

Patient with recurrent ovarian cancer. Maximum intensity projection (MIP) image of FDG-PET study prior to treatment (a) shows widespread avid uptake at multiple sites of metastatic disease in the neck, chest and abdomen. Two months after the start of chemotherapy, follow-up imaging demonstrates no residual FDG-avid tumour sites, consistent with a complete metabolic response.